Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We performed a systematic review and meta-analysis of the literature regarding cardiovascular outcomes of differentiated thyroid cancer (DTC) patients who are on long term thyroid stimulating hormone suppression. Searches were carried out using Prisma guidelines in Medline, Embase, CENTRAL, CINAHL and Scopus databases. Eligible papers were those which investigated discrete cardiovascular clinical outcomes in TSH suppressed patients and meta-analysis of selected studies was performed using Revman 5.4.1. We found a total of 195 879 DTC patients with median length to follow up of 8.6 years (range 5-18.8 years). Analysis showed DTC patients to be at higher risk of atrial fibrillation (HR 1.58, 95% CI 1.40, 1.77), stroke (HR 1.14, 95% CI 1.09, 1.20) and all-cause mortality (HR 2.04, 95% CI 1.02, 4.07). However, there was no difference in risk of heart failure, ischemic heart disease or cardiovascular mortality. These findings suggest that degree of TSH suppression must be titrated to accommodate risk of cancer recurrence and cardiovascular morbidity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2084-3408 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.
Front Oncol
August 2025
Department of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Despite the generally favorable prognosis of differentiated thyroid carcinoma (DTC) following surgery and radioactive iodine (RAI) therapy, approximately 10% of cases eventually develop resistance to RAI. This condition, known as radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), is associated with a poor prognosis, with a 10-year survival rate of only 10% from the time of metastasis detection. The limited availability of safe and effective alternative treatments poses a significant challenge to clinical management.
View Article and Find Full Text PDFEfficacy and safety of anlotinib combined with I seed implantation for iodine-refractory thyroid cancer.
Front Endocrinol (Lausanne)
September 2025
Department of Nuclear Medicine, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.
Background And Objective: Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) remains challenging to treat due to a lack of effective therapies. This study aimed to evaluate the efficacy and safety of combining anlotinib with iodine-125 (I) seed implantation in patients with RAIR-DTC.
Methods And Materials: We retrospectively compared three treatment groups in 52 patients with advanced RAIR-DTC: anlotinib monotherapy (Group A, = 14), I seed brachytherapy monotherapy (Group B, = 25), and combined therapy (Group C, = 13).
Lobectomy or total thyroidectomy in pediatric differentiated thyroid cancer? A systematic review and meta-analysis.
J Pediatr Surg
September 2025
First Department of Pediatric Surgery, Aristotle University of Thessaloniki, General Hospital "G. Gennimatas", Thessaloniki, Greece.
Background: Thyroid cancer in pediatric patients is distinct from adult-onset thyroid cancer due to differences in disease presentation, management and outcomes. This meta-analysis delves into contemporary data on managing pediatric differentiated thyroid cancer (DTC), assessing outcomes, such as recurrence and mortality, in children with radical total thyroidectomy versus the more conservative lobectomy approach.
Methods: MEDLINE (via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), trial registry websites (ClinicalTrials.
Impact of tumor size on oncological and surgical outcomes in robot-assisted transaxillary surgery for papillary thyroid carcinoma.
Eur J Surg Oncol
August 2025
Department of Surgical, Medical, Molecular Pathology, and Critical Care, University of Pisa, Pisa 56124, Italy. Electronic address:
Background: Robot-assisted transaxillary thyroidectomy (RATT) has emerged as a remote access approach for differentiated thyroid carcinoma (DTC), yet data on its oncological efficacy for tumors larger than 3 cm, particularly in European cohorts, remain scarce. This study aimed to evaluate surgical and oncological outcomes of RATT in patients with papillary thyroid carcinoma (PTC), stratified by tumor size.
Materials And Methods: We retrospectively reviewed 270 patients with histologically confirmed PTC who underwent RATT between July 2012 and August 2022 at a single tertiary center.
Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer.
Endocr J
September 2025
Department of Endocrinology and Metabolism, Nagasaki University Hospital, Nagasaki 852-8501, Japan.
Lenvatinib is approved for the first-line treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day, but its high toxicity often necessitates dose reductions and interruptions. To clarify the efficacy and safety of the reduced dose-initiation of lenvatinib, especially for smaller-build and/or frail Asians, we retrospectively examined outcomes of 43 Japanese individuals with RR-DTC who were treated with lenvatinib, focusing on the initial dose. Twenty-three patients initiated lenvatinib at a full-dose (24 mg/day) and 20 patients initiated at a reduced-dose (≤14 mg/day).
View Article and Find Full Text PDF